Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003-2017).
| Autor: | Doka RM, Suter SE, Mastromauro ML, Bennett AL, Hess PR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the American Veterinary Medical Association [J Am Vet Med Assoc] 2022 Sep 01; Vol. 260 (14), pp. 1827-1833. Date of Electronic Publication: 2022 Sep 01. |
| DOI: | 10.2460/javma.21.11.0498 |
| Abstrakt: | Objective: To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy. Animals: 31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017. Procedures: Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests. Results: The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy. Clinical Relevance: Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|